KP 405
Alternative Names: KP-405Latest Information Update: 08 Jan 2024
At a glance
- Originator Kariya Pharmaceuticals
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 04 Jan 2024 Kariya Pharmaceuticals plans a phase 0 trial for Parkinson's disease (In Volunteers and Patients) in January 2024 (NCT06189170)
- 23 Aug 2021 Preclinical trials in Alzheimer's disease in Denmark (unspecified route) before August 2021 (Karia Pharmaceuticals website, August 2021)
- 23 Aug 2021 Preclinical trials in Parkinson's disease in Denmark (unspecified route) before August 2021 (Karia Pharmaceuticals website, August 2021)